COMMENTS ON A PUBLISHED PAPER
Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study TO 
THE EDITOR

Figure 1
AML-BFM 93: failure to achieve blast cell clearance by day 15. Idarubicin vs daunorubicin.
The misinterpretation of subgroup analyses is one of the most common mistakes in the reporting of clinical trials. 1 Creutzig et al 2 fall into this trap in their recent paper on the AML-BFM 93 trial (Leukemia (2001) 348-354). They report that blast cell clearance by day 15 is significantly better for patients treated with idarubicin than with daunorubicin (P = 0.01), but go on to claim that the 'difference was restricted to . . . high risk patients (P = 0.007)'. This conclusion is based on the inappropriate interpretation of P-values within individual subgroups.
Two important factors need to be considered when interpreting subgroup analyses. First, the smaller numbers in each subgroup lead to wider confidence intervals. Especially when, as here, the number of events in one of the groups is much smaller than the other, false negative results may arise: there is a benefit, but the sample size is too small to demonstrate it with statistical significance. Second, when the overall sample is broken down into smaller subgroups, the play of chance means that it is unlikely that the observed treatment effect in the two groups will be the same, even if there is no true difference in effect between them. Thus, in this example, one would expect the point estimate of treatment effect to be greater than the overall estimate in one group and smaller in the other.
The assessment of whether treatment effects differ between subgroups should be based on tests for interaction between subgroups, not on results within individual subgroups. 3 The data reported by Creutzig et al are presented in Figure 1 as an odds ratio plot (our calculations use an odds ratio method, and yield slightly different answers from those in the paper -we find the overall effect has a Pvalue of 0.007). Although there is a significant treatment benefit for idarubicin in one subgroup but not in the other, there is no significant interaction between the two groups (test for heterogeneity: P = 0.5). Consequently there is no good evidence of difference in treatment effect between the subgroups. The evidence for a benefit of idarubicin is stronger in the high risk group, but it cannot be concluded that there is no benefit in the standard risk group. Indeed, the confidence Leukemia interval for standard risk patients is so wide as to be compatible with any effect from a benefit larger than that in high risk patients to an adverse effect of idarubicin. 'Evidence of lack of effect' is very different from 'lack of evidence of effect'. In the standard risk group the latter applies since the CI is so wide as to make the conclusion that there is lack of benefit untenable.
It is instructive to consider what sample size is required to achieve statistical significance given a 52% odds reduction. As the sample size decreases, the P-value increases: the point of statistical significance (P = 0.05) occurs when the subgroup is almost exactly half the size of the total sample. Thus, in a random sample the size of the standard risk group, one would not expect to obtain significance, even if the observed odds reduction were precisely 52%. The point estimate for the odds reduction in the high risk group would also be 52% but, in this subgroup, this would be statistically significant. In this example, the estimate of effect size is the same in both groups, but a simplistic interpretation based only on whether P-values are significant or not might lead to the conclusion that there is benefit in the high risk group but not in the standard risk group.
In the absence of evidence of heterogeneity between subgroups, the most appropriate statistical interpretation of the data presented is to apply the overall result to each subgroup. The appropriate conclusion is therefore that there is evidence of benefit overall, but no evidence that this benefit does not apply to each subgroup. 3 Odds ratio plots help avoid potential misinterpretation by giving a visual picture of the uncertainty surrounding the point estimates and we recommend that subgroup analyses are routinely presented in this way. A test for interaction (heterogeneity or trend as appropriate) should determine whether or not there is evidence of difference in effect between subgroups, rather than individual P-values for each group separately.
The failure to report the appropriate statistical tests and the incorrect interpretation of P-values can potentially have important clinical implications. It might lead to some patients being denied an effective treatment (or being given an ineffective one). Such a possibility is suggested by the statement of Creutzig et al that 'an induction with daunorubicin may be already sufficient for standard risk patients' (though, of course, this report on the AML-BFM 93 study provides no evidence Leukemia that the difference in day 15 blast clearance translates into a longterm survival benefit for idarubicin).
K Wheatley University of Birmingham Clinical Trials Unit, RK Hills
Birmingham, UK
Reply to Wheatley and Hills: interpretation of subgroups in the AML-BFM 93 study
We appreciate the comments from K Wheatley and R Hills. They critize inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study.
In study AML-BFM 93, patients were stratified at diagnosis in standard-and high-risk groups according to FAB morphology. 1 Standardrisk patients were upgraded on day 15 to the high-risk group when presenting with a bone marrow blast count above 5% and received equal intensive treatment as high-risk patients defined by morphology. By contrast, the bone marrow count on day 15 in patients with morphological high-risk criteria had no therapeutic consequences. Bone marrow blast count on day 15 was also the target criterion for the randomisation of ADE vs AIE (ADE, cytosine arabinoside, daunorubicin and etoposide; AIE, idarubicin instead of daunorubicin, Ara-C and etoposide as in ADE). Therefore, a separate analysis of the FABbased risk groups was of special interest and not only one among other subgroup analyses. In that case the criticism of Wheatley and Hills would have been fully justified.
Wheatley and Hills argue that our conclusion that an induction with daunorubicin may already be sufficient for standard-risk patients, might lead to some patients being denied an effective treatment. Perhaps to avoid misunderstandings we should have added that one should not look on the blast count alone. Our specific treatment strategy of shifting standard-risk patients with a bone marrow blast count above 5% on day 15 to the high-risk group might have counterbalanced the slightly higher rate of standard-risk patients with bone marrow blasts above 5% after induction with ADE. The event-free survival is very similar in morphological standard-risk patients treated with either ADE or AIE.
A problem of most medical publications is the large number of partly data-driven statistical tests and the misinterpretation of a Pvalue below 5% as proof for a true effect and a P-value of у5% as proof of equivalence. All tests which are not planned in advance are only descriptive and results need to be interpreted carefully. The proposal to use tests for interaction is useful because it is more conservative. Another approach could be the use of alpha correction procedures. However, being too strict in controlling for type I error might lead to a high probability of overlooking interesting hypotheses which might worth proving in subsequent trials.
Wheatley and Hills recommend odds ratio plots to present sub- As has been stated in the discussion of our paper, all patients of study AML-BFM 87 were treated during induction with daunorubicin. Results for blasts in the bone marrow on day 15 are similar to the ADE arm of study AML-BFM 93. All patients of study AML-BFM 98 now receive idarubicin. Currently, results for the bone marrow blast count on day 15 (patients of study 98 diagnosed before June 2001) are similar to the AIE arm of study AML-BFM 93 (standard risk: 22% patients, high risk 18% patients with у5% blasts in the bone marrow). If we combine the data of studies AML-BFM 87, 93 and 98 for standard-risk patients, the percentage of patients with у5% blasts is 24% (43/181) after ADE and 19% (24/127, 95% CI 13-27%) after AIE. In the high risk group the percentage is 36% (93/257) after ADE and 17% (51/292) after AIE. The odds ratio is 0.75 (95% CI 0.43-1.3) for standard-risk and 0.37 (95% CI 0.25-0.55) for high-risk. The P-value of the test for heterogeneity is 0.046. Thus, the impact of AIE vs ADE on the bone marrow blast count on day 15 seems to be different in both risk groups also by the test proposed by Wheatley and Hills. Whether the reduction from 24% to 19% BM blasts in the SR-group should lead to clinical decisions is a matter of discussion. The longterm survival results of study AML-BFM 98 will help to give recommendations for the use of AIE in standard risk patients in pediatric AML.
M Zimmermann
University Children's Hospital,
U Creutzig
Dept of Hematology/Oncology, Mü nster, Germany
